全部树

Cost of living data for global residentsNEW

China high-tech enterprise patent statisticsNEW

Statistics on entry and exit information of Chinese partnershipsNEW

Patents and citation data of Little Giant and individual champion companiesNEW

Small giant and single champion enterprise design patent details table

Digital economy patent application and authorization dataNEW

Tax investigation of corporate patents and citation dataNEW

Patent and citation data of Chinese industrial enterprisesNEW

Patent and citation data of A-share listed companiesNEW

Patent details of A-share listed companies
A-share listed companies' design patent application details table
Details of Design Patents Authorized by A-share Listed Companies

Statistics on the entry and exit of Chinese industrial and commercial enterprisesNEW

Basic information data of manufacturing industrial and commercial registered enterprisesNEW

China foreign trade index data

China university patent statisticsNEW

Green patents and citation data of Chinese industrial enterprisesNEW

Details of Green Patents of Chinese Industrial Enterprises

Green patents and citation data of A-share listed companies

A-share listed companies green patent details table

  The 2019 novel coronavirus (2019-nCoV), first identified in cases of viral pneumonia in Wuhan in 2019, was officially named by the World Health Organization (WHO) on January 12, 2020. Coronaviruses constitute a large family of viruses known to cause illnesses ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus represents a new strain previously undiscovered in humans.

  On January 21, 2020, the National Health Commission issued Announcement No. 1, classifying pneumonia caused by the novel coronavirus as a Category B infectious disease under the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases, while implementing prevention and control measures typically applied to Category A infectious diseases. Currently, during this critical phase of pandemic response, numerous domestic and international organizations are collaborating to combat the outbreak. Throughout this period, Chinese enterprises have actively contributed to epidemic control efforts by donating supplies and funds.

  To support academic research and epidemic prevention initiatives, the CnOpenData team has compiled a corporate donation dataset related to COVID-19 containment. This database systematically records donation amounts, recipients, and timelines of companies nationwide. We have made this corporate donation data openly accessible to researchers and the public (contact customer service for access), with the aspiration of accelerating the successful containment of the pandemic.


Field Descriptions


Database Usage Guide

Reprint: Intensity and Orientation: A Portrait of COVID-19 Donations from Top 500 Chinese Private Enterprises


Sample Data


Data Update Frequency

Annual updates